Charting the multilevel molecular response to palbociclib in ER-positive breast cancer
{{output}}
The addition of CDK4/6 inhibitors to endocrine therapy has significantly improved outcomes in HR+/HER2- breast cancer (BC). However, variable patient responses and acquired resistance remain a clinical challenge. We therefore defined the comprehensive molecula... ...
